Injective (INJ) is currently trading at $3.25, experiencing a 24-hour price decline of 5.05%. The daily trading range has been relatively narrow, with a high of $3.42 and a low of $3.24, indicating limited volatility in the short term.

The trading volume stands at approximately 42.8 million, representing 13.16% of the market cap. This volume level suggests moderate interest in INJ, although the declining price may indicate a lack of bullish momentum among traders.

Technical indicators show that short-term moving averages (8 SMA, 13 SMA, 21 SMA, and 55 SMA) are all trending downward, reflecting bearish sentiment. However, the 144 SMA indicates a potential support level at $3.15, which could provide a buffer against further declines.

The RSI metrics show a mixed picture: the 1-hour RSI is at a low of 19, signaling oversold conditions, while the 7-day RSI is at 56, suggesting neutrality. This discrepancy indicates that while the asset may be oversold in the very short term, it maintains a stable position over the week.

Over the past 30 days, INJ has shown a price change of approximately 9.10%, and the 14-day change is significantly positive at around 15.88%. This longer-term trend suggests potential for recovery, but the recent 24-hour decline casts doubt on immediate upward momentum.

Despite the oversold condition indicated by the 1-hour RSI, the overall trend and recent performance suggest caution. The current price is below critical moving averages, and unless there is a significant turnaround in market sentiment or volume, the short-term outlook remains negative.

Given the technical indicators and the current market environment, a Sell rating is warranted. The recent price action and bearish moving averages indicate that INJ may continue to face downward pressure in the near term, warranting a cautious approach for traders.